<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066258</url>
  </required_header>
  <id_info>
    <org_study_id>RGX-314-001</org_study_id>
    <nct_id>NCT03066258</nct_id>
  </id_info>
  <brief_title>RGX-314 Gene Therapy for Neovascular AMD Trial</brief_title>
  <official_title>A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenxbio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenxbio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Excessive vascular endothelial growth factor (VEGF) plays a key part in promoting
      neovascularization and edema in neovascular (wet) age-related macular degeneration (nAMD).
      VEGF inhibitors (anti-VEGF), including ranibizumab (LUCENTIS®, Genentech) and aflibercept
      (EYLEA®, Regeneron), have been shown to be safe and effective for treating nAMD and have
      demonstrated improvement in vision. However, anti-VEGF therapy is administered frequently
      via intravitreal injection and can be a significant burden to the patients. RGX-314 is a
      recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for
      a soluble anti-VEGF protein. The long-term, stable delivery of this therapeutic protein
      following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment
      burden of currently available therapies while maintaining vision with a favorable
      benefit:risk profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I, open-label, multiple-cohort, dose-escalation study is designed to evaluate the
      safety and tolerability of RGX-314 gene therapy in subjects with previously treated nAMD.
      Three doses will be studied in approximately 18 subjects. Subjects who meet the
      inclusion/exclusion criteria and have an anatomic response to an initial anti VEGF injection
      will receive a single dose of RGX-314 administered by subretinal delivery. RGX-314 uses an
      AAV8 vector that contains a gene that encodes for a monoclonal antibody fragment which binds
      to and neutralizes VEGF activity. Safety will be the primary focus for the initial 24 weeks
      after RGX-314 administration (primary study period). Following completion of the primary
      study period, subjects will continue to be assessed until 104 weeks following treatment with
      RGX-314.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (incidence of ocular and non-ocular AEs and SAEs)</measure>
    <time_frame>26 weeks</time_frame>
    <description>incidence of ocular and non-ocular AEs and SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (incidence of ocular and non-ocular AEs and SAEs)</measure>
    <time_frame>106 weeks</time_frame>
    <description>incidence of ocular and non-ocular AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity</measure>
    <time_frame>106 weeks</time_frame>
    <description>BCVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central retinal thickness</measure>
    <time_frame>106 weeks</time_frame>
    <description>CRT as measured by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue injections (Mean number of rescue injections)</measure>
    <time_frame>106 weeks</time_frame>
    <description>Mean number of rescue injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in area of CNV</measure>
    <time_frame>106 weeks</time_frame>
    <description>Area of CNV and leakage measured by FA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Wet Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3E9 GC of RGX-314</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1E10 GC of RGX-314</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6E10 GC of RGX-314</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RGX-314</intervention_name>
    <description>RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 50 years with a diagnosis of subfoveal CNV secondary to AMD in the study
             eye receiving prior intravitreal anti-VEGF therapy.

          2. BCVA between ≤20/100 and ≥20/400 (≤65 and ≥35 Early Treatment Diabetic Retinopathy
             Study [ETDRS] letters) for the first patient in each cohort followed by BCVA between
             ≤20/63 and ≥20/400 (≤75 and ≥35 ETDRS letters) for the rest of the cohort.

          3. History of need for and response to anti-VEGF.therapy.

          4. Response to anti-VEGF at trial entry (assessed by SD-OCT at week 1)

          5. Must be pseudophakic (status post cataract surgery) in the study eye.

          6. AST/ALT &lt; 2.5 × ULN; TB &lt; 1.5 × ULN; PT &lt; 1.5 × ULN; Hb &gt; 10 g/dL (males) and &gt; 9
             g/dL (females); Platelets &gt; 100 × 10^3/µL; eGFR &gt; 30 mL/min/1.73 m^2

          7. Must be willing and able to provide written, signed informed consent.

        Exclusion Criteria:

          1. CNV or macular edema in the study eye secondary to any causes other than AMD.

          2. Any condition preventing visual acuity improvement in the study eye, eg, fibrosis,
             atrophy, or retinal epithelial tear in the center of the fovea.

          3. Active or history of retinal detachment in the study eye.

          4. Advanced glaucoma in the study eye.

          5. History of intravitreal therapy in the study eye, such as intravitreal steroid
             injection or investigational product, other than anti-VEGF therapy, in the 6 months
             prior to screening.

          6. Presence of an implant in the study eye at screening (excluding intraocular lens).

          7. Myocardial infarction, cerebrovascular accident, or transient ischemic attacks within
             the past 6 months.

          8. Uncontrolled hypertension (systolic blood pressure [BP] &gt;180 mmHg, diastolic BP &gt;100
             mmHg) despite maximal medical treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Heier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Boston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rickey Reinhardt, MD, PhD</last_name>
    <phone>2405528181</phone>
    <email>rreinhardt@regenxbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Wilmer Eye Institute at Johns Hopkins Hospital School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gulnar Hafiz, MD</last_name>
      <phone>410-937-3662</phone>
      <email>ghafiz1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Cammarata</last_name>
      <phone>617-573-1023</phone>
      <email>dcammarata@eyeboston.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Center for Advanced Retinal and Ocular Therapeutics</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denise Pearson, COMT</last_name>
      <phone>215-662-6396</phone>
      <email>Denise.Pearson@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brianna Kenney</last_name>
      <phone>215-928-3092</phone>
      <email>bkenney@midatlanticretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charles Retina Institute</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melanie Woods</last_name>
      <phone>901-683-0399</phone>
      <email>mwoods@charlesretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cassandra Cone</last_name>
      <phone>713-394-7537</phone>
      <email>cassandra.cone@houstonretina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 23, 2017</lastchanged_date>
  <firstreceived_date>February 17, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nAMD</keyword>
  <keyword>wet AMD</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
